Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2
3(60.0%)
Phase 1
2(40.0%)
5Total
Phase 2(3)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT02660489Phase 2Completed

Effect of OC459 on the Response to Rhinovirus Challenge in Asthma

Role: collaborator

NCT02560610Phase 2Completed

Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma

Role: collaborator

NCT02002208Phase 2Completed

Effect of OC000459 on Moderate to Severe Atopic Dermatitis

Role: lead

NCT02316912Phase 1Completed

First in Man Evaluation of Single and Multiple Doses of Oral ATX2417

Role: lead

NCT02341521Phase 1Completed

Evaluation of Metabolic Profile of OC000459

Role: lead

All 5 trials loaded